Abstract:Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention over the last 10 years, representing a burgeoning therapeutic approach with the potential to address pathogenic proteins that have historically posed challenges for traditional small-molecule inhibitors. PROTACs exploit the endogenous E3 ubiquitin ligases to facilitate degradation of the proteins of interest (POIs) through the ubiquitin–proteasome system (UPS) in a cyclic catalytic manner. Despite recent endeavors to advance the utilization of PROTACs in clinical settings, the majority of PROTACs fail to progress beyond the preclinical phase of drug development. There are multiple factors impeding the market entry of PROTACs, with the insufficiently precise degradation of favorable POIs standing out as one of the most formidable obstacles. Recently, there has been exploration of new-generation advanced PROTACs, including small-molecule PROTAC prodrugs, biomacromolecule-PROTAC conjugates, and nano-PROTACs, to improve the in vivo efficacy of PROTACs. These improved PROTACs possess the capability to mitigate undesirable physicochemical characteristics inherent in traditional PROTACs, thereby enhancing their targetability and reducing off-target side effects. The new-generation of advanced PROTACs will mark a pivotal turning point in the realm of targeted protein degradation. In this comprehensive review, we have meticulously summarized the state-of-the-art advancements achieved by these cutting-edge PROTACs, elucidated their underlying design principles, deliberated upon the prevailing challenges encountered, and provided an insightful outlook on future prospects within this burgeoning field.

PROTACs in Gynecological Cancers: Current Knowledge and Future Potential as a Treatment Strategy

Current Advancements and Future Perspectives

Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

PROTACs in the Management of Prostate Cancer

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer

PROTACs in gastrointestinal cancers

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

PROTAC: novel degradable approach for different targets to treat breast cancer

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology

Development of PROTAC Degrader Drugs for Cancer

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

Development of the non-receptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]

PROTACs As Potential Therapeutic Agents for Cancer Drug Resistance.

PROTAC therapy as a new targeted therapy for lung cancer

Recent Advances in Optically Controlled PROTAC

Targeted protein degradation in cancers: Orthodox PROTACs and beyond